KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

BackgroundKRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studied...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Emerik Osterlund, Ari Ristimäki, Soili Kytölä, Teijo Kuopio, Eetu Heervä, Timo Muhonen, Päivi Halonen, Raija Kallio, Leena-Maija Soveri, Jari Sundström, Mauri Keinänen, Annika Ålgars, Raija Ristamäki, Halfdan Sorbye, Per Pfeiffer, Luís Nunes, Tapio Salminen, Annamarja Lamminmäki, Markus J. Mäkinen, Tobias Sjöblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-02-01
coleção:	Frontiers in Oncology
Assuntos:	colorectal cancer metastatic KRAS mutation KRAS-G12C mutation population-based real-world
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.826073/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!